Accessible text: pCPA Dashboard

Accessible text for the pCPA February 2026 Dashboard

Data effective: December 31, 2025

For questions regarding this report, please contact: [email protected]

Letters of intent (LOIs)

Since the pCPA’s inception, 768 negotiations have reached a letter of intent (LOI), including:

  • 270 for oncology drugs
  • 92 biosimilars
  • 93 drugs for rare diseases (DRD)
Data for stacked line graph: Letters of intent
MonthBiosimilarDRDOther non-oncologyOther oncology
Jun 2015064024
Jul 2015064225
Aug 2015064426
Sep 2015064626
Oct 2015064827
Nov 2015064828
Dec 2015164830
Jan 2016165130
Feb 2016165230
Mar 2016165431
Apr 2016175731
May 2016176131
Jun 2016176232
Jul 2016176333
Aug 2016176434
Sep 2016186634
Oct 20161116636
Nov 20162126737
Dec 20162126837
Jan 20173126937
Feb 20173126941
Mar 20173127641
Apr 20173128141
May 20173128341
Jun 20173138344
Jul 20174138647
Aug 20175138748
Sep 20175148750
Oct 20175148751
Nov 20176158951
Dec 20176169156
Jan 20186179559
Feb 20186189660
Mar 201861810060
Apr 201861810161
May 201861910261
Jun 201862010262
Jul 201862110363
Aug 201872210766
Sep 201872411267
Oct 201872511567
Nov 201872511767
Dec 201872812070
Jan 201972812572
Feb 201972812575
Mar 201982813176
Apr 201982813281
May 201982813482
Jun 201982813682
Jul 201982913982
Aug 201993014283
Sep 2019103014487
Oct 2019113014789
Nov 2019133014991
Dec 2019143015794
Jan 2020143015894
Feb 2020143115895
Mar 2020153315997
Apr 2020153316198
May 20201635163104
Jun 20201635163104
Jul 20201936163105
Aug 20202036166108
Sep 20202036166109
Oct 20202136166110
Nov 20202138167112
Dec 20202239168114
Jan 20212239179115
Feb 20212739181116
Mar 20212740185118
Apr 20212840185119
May 20213040185121
Jun 20213140186122
Jul 20213142187122
Aug 20213142188124
Sep 20213342192129
Oct 20213444196129
Nov 20213645197133
Dec 20213645200134
Jan 20223645202138
Feb 20223746202141
Mar 20223847203147
Apr 20224148207148
May 20224148209149
Jun 20224648209152
Jul 20224649210153
Aug 20224650210155
Sep 20224651216158
Oct 20224653218159
Nov 20224656218162
Dec 20224857220165
Jan 20234857221168
Feb 20234958224168
Mar 20234959224168
Apr 20235160226181
May 20235162230181
Jun 20235264231190
Jul 20235265233192
Aug 20235366234194
Sep 20235466236195
Oct 20235466239196
Nov 20235669240199
Dec 20235669242201
Jan 20245670245202
Feb 20245773247202
Mar 20245873248205
Apr 20245873249206
May 20245874256206
Jun 20246074260207
Jul 20246374263208
Aug 20246374264214
Sep 20246374265220
Oct 20246375267222
Nov 20246376271225
Dec 20246678271228
Jan 20256679271229
Feb 20256680271234
Mar 20256980276239
Apr 20257380280242
May 20257480283247
Jun 20257582285249
Jul 20257784287256
Aug 20257888287259
Sep 20258891290260
Oct 20259192291262
Nov 20259292295268
Dec 20259293299270

Savings

pCPA activities saved jurisdictions an estimated $4.87B in 2024–25:

  • $3.94B from brand name drugs
  • $935M from generic drugs
  • Since 2010, cumulative savings are estimated to be $28.8B
Data for stacked bar chart: Savings
Fiscal YearBrand name drugsGeneric drug negotiationsTotal
FY 16/17$947,007,363$355,000,000$1,302,007,363
FY 17/18$1,263,644,399$740,000,000$2,003,644,399
FY 18/19$1,539,331,475$740,000,000$2,279,331,475
FY 19/20$1,847,496,049$740,000,000$2,587,496,049
FY 20/21$2,185,315,806$740,000,000$2,925,315,806
FY 21/22$2,667,069,216$750,000,000$3,417,069,216
FY 22/23$3,142,207,211$750,000,000$3,892,207,211
FY 23/24$3,715,798,849$913,979,661$4,629,778,510
FY 24/25$3,940,000,000$935,000,000$4,875,000,000

HTA and pCPA volumes

  • The pCPA engaged and concluded a record number of negotiations in 2025, in response to sustained high volume of health technology assessment (HTA) reimbursement recommendations in recent years.
  • Numbers of HTA reimbursement recommendations are expected to be similar in 2026 as those in 2025, and pCPA negotiation volumes are also projected to be similar.
Data for bar charts: HTA and PCPA volumes

Three bar charts tracking number of HTA recommendations issued, pCPA negotiations engaged, and pCPA negotiations concluded.

YearHTA recommendations issuedpCPA negotiations engagedpCPA negotiations concluded
2020577068
2021658574
2022828390
2023618193
2024789879
202576122137

pCPA activity

  • The number of files under consideration has moderately increased from summer 2025.
  • The pCPA is committed to further decreasing the time under consideration.
  • The number of active negotiations remained strong after hitting a record high in the summer of 2025.
Data for line graphs: pCPA activity

Two line graphs:

  • "Files under consideration" represents files between the HTA recommendation and pCPA engagement.
  • "Active negotiations" are files that have been engaged but have not concluded.
MonthFiles under consideration (average)Active Negotiations (average)
Jan 202128.7533.4
Feb 202127.1933.25
Mar 202125.6335.13
Apr 202126.5633.5
May 202129.5533.3
Jun 202128.6934.94
Jul 202128.6943
Aug 202129.944.5
Sep 202134.3839.5
Oct 202135.4536.25
Nov 202128.6341.5
Dec 202123.4446.06
Jan 202225.343.25
Feb 202228.3843
Mar 202231.8844.06
Apr 202232.3844.13
May 202232.542.2
Jun 202230.1935.31
Jul 202229.735.1
Aug 202230.9436.5
Sep 202234.5632.81
Oct 202238.631.2
Nov 202236.8134.5
Dec 202238.4434.19
Jan 202335.7535.75
Feb 202337.537.94
Mar 202336.0642
Apr 202333.836.2
May 202330.6333.25
Jun 202327.5633.56
Jul 202326.5531.6
Aug 202325.8826.5
Sep 202324.3828.69
Oct 202323.928.15
Nov 202324.4424.25
Dec 202327.8524.6
Jan 202427.0623.56
Feb 202427.7522.13
Mar 20242926.65
Apr 202430.3132.06
May 202432.8129.88
Jun 202440.6525.5
Jul 202440.1325.31
Aug 202433.2527.81
Sep 202422.838.25
Oct 202419.3841.56
Nov 202418.542.13
Dec 202421.444.6
Jan 202525.545.88
Feb 202525.7546.19
Mar 202519.245.5
Apr 202515.1944.38
May 202512.8142.31
Jun 202513.538.75
Jul 202512.537.38
Aug 202516.6544.2
Sep 201519.5640.69
Oct 202520.8137
Nov 202521.4535.6
Dec 202519.1931.81

pCPA timelines

  • Between 2020 and 2025, the typical time under consideration improved from 99 business days to 32 business days, a 67% decrease.
    Between 2020 and 2025, the total timeline improved from 219 business days to 81 business days, a 63% decrease.
Data for bar chart: pCPA timelines

* Not all negotiations initiated in 2025 have concluded. The pCPA expects that as outstanding negotiations conclude, median timelines for 2025 will increase to be similar to 2024 timelines.

Data is measured in median business days.

YearRecommendation to acknowledgmentAcknowledgment to negotiation startNegotiation start to conclusionTotal median business days
2020899112219
202146886158
202278074160
202367380159
202466270138
20258324181

Oncology drugs

  • Timelines have improved for both time under consideration and active negotiation since 2020 for oncology drugs. The median time for under consideration has decreased from 45 business days, in 2020 to 30 business days in 2025. For time spent actively negotiating, timelines have decreased from a median of 103 business days to 40 business days.*
Data for bar chart: Oncology drugs

*Not all negotiations initiated in 2025 have concluded. The pCPA expects that as outstanding negotiations conclude, median timelines for 2025 will increase to be similar to 2024 timelines.

Data is measured in median business days.

YearRecommendation to acknowledgmentAcknowledgment to negotiation startNegotiation start to conclusionTotal median business days
2020945103156
202146478146
202256273140
202365476136
202453771113
20258304078